CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
Alemtuzumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03989466
NCT03989466Phase 1Completed
CompareCT.gov

Phase Ib Pilot Study of Itacitinib With Alemtuzumab in Patients With T-Cell Prolymphocytic Leukemia (T-PLL)

M.D. Anderson Cancer Center·interventional·Posted Jun 18, 2019·Updated Oct 10, 2024

In Brief

A Phase 1 clinical trial evaluating Alemtuzumab and Itacitinib for Recurrent T-Cell Prolymphocytic Leukemia and T-Cell Prolymphocytic Leukemia. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may work better in treating patients with T-cell prolymphocytic leukemia compared to standard of care treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJun 18, 2019
Enrollment StartJan 15, 2020
Primary CompletionSep 24, 2024
TodayJul 1, 2026
Enrollment to primary: 4.7 yearsPosted 7.0 years ago

Interventions

Alemtuzumabbiological

Given IV

Itacitinibdrug

Given PO